£12m loss recorded at UK Sunday Times top 100 business

Genomics, founded in 2014, increased its operating loss for the year from £9.9m in the 12 months ending December 2024 to £12.1m in 2025.

Based at King Charles House in the city centre’s Park End Street, the business specialises in clinical DNA diagnostic testing.

It decodes DNA to diagnose rare diseases, predicts genetic health risks and accelerates new targeted medical treatments.

READ MORE: Rolling Stones legends come together to mark major day

Revenue for Genomics rose once again over the 12 month period to £14.1m, up about 27 per cent year-on-year.

But the huge and increasing loss has been attributed to continued investment by the business.

Professor Peter Donnelly, chief executive, said in a report: “This reflects a specific and deliberate investment strategy focused on the long-term development of the business, comprising planned investment in staff and product development to strengthen and scale the group’s commercial offering.

“Central to this was the launch of Mystra, the group’s proprietary, self-service platform for drug discovery and data analytics.

“The increased loss reflects these investments in the future of the business and strengthening its foundations for long-term growth.”

But despite the operating loss, Genomics says its revenue growth has been recognised through its inclusion in the Sunday Times 100 tech 2026 list of the UK’s fastest growing private tech firms.

More than 140 people are employed at the Oxford-based company including more than 60 PhD-qualified professionals and one of the world’s strongest statistical genetics teams.